Top Page
dorsaVi Limited
(Sydney:DVL)
dorsaVi Limited (DVL) vs. iShares MSCI Australia ETF (EWA)
dorsaVi Limited Business Overview & Revenue Model
dorsaVi Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.13M | 1.13M | 1.30M | 1.75M | 2.35M | 1.87M |
| Gross Profit | 971.82K | 971.82K | 1.18M | -798.43K | -1.45M | -1.74M |
| EBITDA | -1.82M | -1.82M | -1.60M | -1.88M | -1.53M | -2.29M |
| Net Income | -1.52M | -1.52M | -1.25M | -1.82M | -1.54M | -2.41M |
Balance Sheet | ||||||
| Total Assets | 3.97M | 3.97M | 2.18M | 2.69M | 3.36M | 5.42M |
| Cash, Cash Equivalents and Short-Term Investments | 2.29M | 2.29M | 478.10K | 878.72K | 449.70K | 2.80M |
| Total Debt | 156.89K | 156.89K | 190.17K | 321.85K | 1.18M | 1.18M |
| Total Liabilities | 1.14M | 1.14M | 1.16M | 1.01M | 2.13M | 2.95M |
| Stockholders Equity | 2.84M | 2.84M | 1.02M | 1.68M | 1.22M | 2.48M |
Cash Flow | ||||||
| Free Cash Flow | -956.83K | -956.83K | -622.08K | -1.02M | -2.25M | -2.36M |
| Operating Cash Flow | -956.83K | -956.83K | -600.90K | -967.41K | -2.15M | -2.27M |
| Investing Cash Flow | -304.00K | -304.00K | -21.18K | -51.65K | -100.34K | -85.41K |
| Financing Cash Flow | 3.08M | 3.08M | 227.06K | 1.45M | -92.25K | 3.47M |
dorsaVi Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
44 Neutral | AU$4.91M | -1.42 | ― | ― | -4.86% | 64.36% | |
41 Neutral | AU$9.12M | -0.32 | ― | ― | -51.64% | -21.74% | |
39 Underperform | AU$40.60M | -17.50 | -78.66% | ― | -13.40% | 4.76% | |
38 Underperform | AU$7.35M | -0.54 | -135.89% | ― | -21.60% | -657.00% | |
37 Underperform | AU$5.29M | -0.76 | -283.40% | ― | -74.76% | 42.11% |
dorsaVi Limited Corporate Events
DorsaVi Ltd has reported the expiry of 1,171,178 listed options (ASX code DVLAA), which were scheduled to expire on various dates and at various exercise prices, and have now lapsed without being exercised. The cessation of these options slightly reduces the company’s pool of potential dilutive securities, simplifying its capital structure and clarifying the current issued capital position for existing shareholders and the market.
The most recent analyst rating on (AU:DVL) stock is a Sell with a A$0.04 price target. To see the full list of analyst forecasts on dorsaVi Limited stock, see the AU:DVL Stock Forecast page.
dorsaVi Limited has notified shareholders that it will hold its 2026 Extraordinary General Meeting as a virtual event on 23 January 2026, in line with Australian corporate regulations allowing electronic communication of meeting materials instead of mailing physical copies by default. The company is encouraging investors to participate by lodging directed proxy votes ahead of the deadline and to submit questions in advance, while also flagging that meeting arrangements may change subject to evolving conditions, underscoring an ongoing shift toward digital governance practices and flexible shareholder engagement.
The most recent analyst rating on (AU:DVL) stock is a Sell with a A$0.04 price target. To see the full list of analyst forecasts on dorsaVi Limited stock, see the AU:DVL Stock Forecast page.
dorsaVi Limited has called an extraordinary general meeting of shareholders to be held virtually on 23 January 2026, with voting primarily conducted via proxy and online participation through a webinar platform. Shareholders will be asked to approve the issue of up to 80 million consideration shares to vendors under Listing Rule 7.1 and to approve the grant of performance rights to director Gernot Abl, decisions that could significantly impact the company’s capital structure, ownership mix and executive incentives, and thereby influence governance and future strategic direction.
The most recent analyst rating on (AU:DVL) stock is a Sell with a A$0.04 price target. To see the full list of analyst forecasts on dorsaVi Limited stock, see the AU:DVL Stock Forecast page.
dorsaVi Limited has issued 2,342,009 fully paid ordinary shares under provisions of the Corporations Act that allow share issuance without a disclosure document, and has lodged a cleansing notice confirming compliance with its continuous disclosure and financial reporting obligations. The company also stated that, as at the date of the notice, it is not aware of any excluded information that would need to be disclosed, a step that helps maintain secondary trading liquidity for the new shares and signals adherence to governance and regulatory requirements for existing and prospective shareholders.
The most recent analyst rating on (AU:DVL) stock is a Sell with a A$0.04 price target. To see the full list of analyst forecasts on dorsaVi Limited stock, see the AU:DVL Stock Forecast page.
dorsaVi Limited has applied to the ASX for quotation of 2,342,009 new fully paid ordinary shares under the code DVL, with the securities issued on 23 December 2025. The additional quoted shares, which arise from previously announced transactions, will modestly expand the company’s free float and equity base, potentially enhancing liquidity in its stock and supporting ongoing corporate and capital management initiatives for existing and prospective shareholders.
The most recent analyst rating on (AU:DVL) stock is a Sell with a A$0.04 price target. To see the full list of analyst forecasts on dorsaVi Limited stock, see the AU:DVL Stock Forecast page.
dorsaVi Limited has notified the market of the planned issuance of 20 million unlisted options, each exercisable at $0.075 and expiring on 23 December 2028. The move increases the company’s pool of unquoted equity securities and may form part of its broader capital management or incentive arrangements, potentially affecting future dilution and aligning stakeholders with the company’s long‑term performance.
The most recent analyst rating on (AU:DVL) stock is a Sell with a A$0.04 price target. To see the full list of analyst forecasts on dorsaVi Limited stock, see the AU:DVL Stock Forecast page.
DorsaVi Ltd has notified the market of the issue of 24 million unquoted performance rights, designated under ASX code DVLAG, which are not intended to be quoted on the ASX. The move, disclosed via an Appendix 3G filing, signals a significant new tranche of equity-based incentives that could impact the company’s future capital structure and align management or key personnel with longer-term performance objectives.
The most recent analyst rating on (AU:DVL) stock is a Sell with a A$0.04 price target. To see the full list of analyst forecasts on dorsaVi Limited stock, see the AU:DVL Stock Forecast page.
dorsaVi Limited has notified the market of the issue of 62.5 million new unlisted options, each exercisable at $0.075 and expiring on 23 December 2028. The options, which are part of a previously announced transaction and are not intended to be quoted on the ASX, expand the company’s pool of unquoted equity instruments and may provide additional incentive or funding flexibility for the business, with potential dilution implications for existing shareholders if exercised.
The most recent analyst rating on (AU:DVL) stock is a Sell with a A$0.04 price target. To see the full list of analyst forecasts on dorsaVi Limited stock, see the AU:DVL Stock Forecast page.
dorsaVi Limited has notified the market of the issue of 24 million unquoted performance rights under the ASX code DVLAG, effective 23 December 2025. The new securities, which are not quoted and are not intended to be quoted on the ASX, form part of a previously announced transaction, signalling the company’s continued use of equity-based incentives or structures that may influence future capital structure and management or employee alignment, with potential dilutionary implications for existing shareholders over time.
The most recent analyst rating on (AU:DVL) stock is a Sell with a A$0.04 price target. To see the full list of analyst forecasts on dorsaVi Limited stock, see the AU:DVL Stock Forecast page.
DorsaVi Limited has announced significant progress in its RRAM development program, which is crucial for the company’s future biosensing and edge-intelligent systems. The collaboration with Artemis Labs aims to optimize RRAM for integration at the 22nm technology node, enhancing its performance for neuromorphic and edge-AI applications. This development positions DorsaVi to capitalize on the growing edge AI market, projected to expand significantly by 2030, by providing advanced silicon solutions for wearables, robotics, and industrial safety products.
The most recent analyst rating on (AU:DVL) stock is a Sell with a A$0.04 price target. To see the full list of analyst forecasts on dorsaVi Limited stock, see the AU:DVL Stock Forecast page.
dorsaVi Limited announced the successful passing of all resolutions at its annual general meeting, including a special resolution. This development is significant for the company as it reflects shareholder support for its strategic initiatives and governance. The resolutions passed include the adoption of the remuneration report, election of a new director, and approval of performance rights and placement shares, which are crucial for the company’s operational and financial strategies moving forward.
dorsaVi Limited has acquired a groundbreaking neuromorphic technology portfolio from Technion, led by Prof. Shahar Kvatinsky. This acquisition positions dorsaVi at the forefront of next-generation robotics and wearable intelligence by integrating Processing-in-Memory (PIM) technology, which combines computation and memory into a single intelligent substrate. This strategic move transforms dorsaVi’s biosensors into autonomous nodes capable of local sensing, thinking, and acting, thereby advancing the company’s shift from reactive analytics to self-adapting edge systems. The acquisition is expected to significantly impact the global neuromorphic-computing market, which is projected to grow substantially by 2030, highlighting the rising demand for on-device intelligence.
DorsaVi Limited, a company listed on the Australian Securities Exchange, has requested a trading halt for its ordinary shares. This halt is pending an announcement related to a proposed acquisition, which is expected to be made before the commencement of normal trading on 13 November 2025. The trading halt is intended to help the company manage its continuous disclosure obligations.
dorsaVi Limited has announced the cessation of Andrew James Ronchi as a director of the company, effective November 1, 2025. This change in leadership involves a significant number of shares and options held by Ronchi, reflecting his substantial financial interest in the company. The announcement may impact the company’s governance structure and could have implications for its strategic direction and stakeholder relationships.
dorsaVi Limited has announced the commencement of an evaluation program to scale its oxide-based RRAM from 40 nm to a 22 nm process node. This initiative aims to achieve higher density, lower energy consumption, and faster switching speeds, enhancing the company’s positioning in the embedded non-volatile memory and AI-driven systems markets. The 22 nm evaluation is expected to significantly improve device performance, battery life, and responsiveness, which could strengthen dorsaVi’s competitive edge in the wearables and industrial safety sectors.
dorsaVi Limited has appointed Mathew Regan as the new Group Chief Executive Officer, effective November 1, 2025. Regan, with a strong background in digital health, AI, and advanced manufacturing, is expected to lead the company through a pivotal phase of growth. His previous success at Artrya Limited in reshaping AI-driven platforms and securing FDA clearances positions him well to drive dorsaVi’s global expansion and commercialization of next-generation technologies. The company is focusing on leveraging its RRAM-enabled sensor capabilities across multiple industries, with initiatives like the Reflex platform and the launch of Artemis Labs to accelerate development in robotics and human-machine interfaces.
dorsaVi Limited has initiated a process to engage with semiconductor development partners to explore scaling down its oxide-based Resistive Random-Access Memory (RRAM) technology to the 22 nm process node. This move aims to enhance the technology’s density, speed, and power efficiency, crucial for next-generation edge and wearable computing systems. The 22 nm node is recognized for its manufacturability and performance, providing a solid foundation for dorsaVi’s adaptive RRAM arrays in applications such as biosensing and robotics, where low latency and independence from cloud computing are essential. The company plans to establish a joint evaluation plan with selected partners to guide future developments and potential foundry engagement, marking a significant step in advancing their sensor and robotics products into more intelligent systems.
dorsaVi Limited has made significant strides in its RRAM sensor technology, initiating comprehensive testing in Singapore for biomedical applications such as electromyography and electrocardiography. The company has also signed a five-year sales agreement with a major U.S. physical therapy franchise, indicating strong market expansion potential. Additionally, dorsaVi’s ViMove+ product is showing promising growth in the U.S. market, with acquisition trends significantly higher than historical rates. The company’s financial position has strengthened with a cash balance increase, supported by a successful $5.0 million placement to accelerate RRAM and robotics technology development.
dorsaVi Limited has announced a proposed issue of 2,342,009 ordinary fully paid securities, with an expected issue date of December 3, 2025. This move aims to strengthen the company’s financial position and potentially enhance its market presence, offering significant implications for its stakeholders and industry positioning.
dorsaVi Limited has announced a proposed issue of 24 million performance rights, with the issue date set for December 3, 2025. This move is part of a placement or other type of issue, indicating a strategic effort to potentially raise capital or incentivize stakeholders, which could impact the company’s operations and market positioning within the health technology sector.
dorsaVi Limited has announced its 2025 Annual General Meeting scheduled for November 26, 2025, in Melbourne. Shareholders are encouraged to vote by proxy due to potential changes in meeting conditions, and the company emphasizes digital access to meeting documents to streamline communication and ensure shareholder engagement.
dorsaVi Limited has announced its upcoming Annual General Meeting scheduled for November 26, 2025, in Melbourne. Key agenda items include the adoption of the Remuneration Report, the election of Mr. Leigh Travers as a Director, and the approval of issuing Performance Rights to Mr. Mathew Regan. These resolutions, if passed, could influence the company’s governance structure and executive compensation, potentially impacting its strategic direction and stakeholder relations.